Can I start Wegovy at 0.5 mg if I tolerated Ozempic at 0.5 mg?

Many clinicians do allow this because the molecule and dose are identical. It is technically off-label per the Wegovy insert but follows the same titration logic, since GI adaptation has already happened on Ozempic.

Can I start Wegovy at 1.0 mg or 2.4 mg?

Not per the FDA label. Even patients with prior GLP-1 exposure should not jump to a maintenance dose without working through the ladder. Skipping multiple rungs sharply raises GI side effects and dehydration risk.

What is the starting dose of Wegovy?

0.25 mg once weekly for the first four weeks, subcutaneous injection. This is the FDA-approved starting dose for every adult patient.

Can I stay on a low dose of Wegovy long term?

The FDA approved 2.4 mg as the maintenance dose. The label allows continued use at 1.7 mg if 2.4 mg is intolerable. Staying at 0.5 mg or 1.0 mg long term is not the labeled use but happens in practice when patients have hit their goal weight or cannot tolerate higher doses.

How long does Wegovy take to start working at 0.25 mg?

Most patients notice reduced appetite within the first two weeks at 0.25 mg. Meaningful weight loss typically begins once the dose climbs to 1.0 mg or higher, usually around weeks 9 to 12.

Can I take two 0.25 mg Wegovy shots in the same week to equal 0.5 mg?

No. Wegovy is dosed weekly because of its seven-day half-life. Stacking two 0.25 mg doses in one week is not the same pharmacokinetically as a single 0.5 mg dose and is not supported by the label.

Going from 0.25 to 0.5 mg, what should I expect?

A second wave of mild nausea is common in the first week or two at 0.5 mg. It typically eases as your body adapts. If symptoms are severe or persist beyond two to three weeks, talk to your prescriber about holding at 0.25 mg longer.

How many doses are in a Wegovy pen?

Each Wegovy pen contains a single weekly dose. One pen, one injection, one week. The Wegovy pen is not a multi-dose device the way some Ozempic pens are.

Do you have to increase the Wegovy dose?

The label is built around reaching 2.4 mg for maintenance. Real-world prescribers sometimes stop the titration earlier if a patient is losing weight steadily at a lower dose and has GI side effects at the next step. That decision belongs to your prescriber.

Do you lose more weight on higher doses of Wegovy?

Yes, on average. STEP trial data shows a clear dose-response between 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg. Individual response varies, but the highest mean weight loss in STEP 1 came from the 2.4 mg arm.

Can I Start Wegovy at 0.5 mg?

Summary: The short answer is no. The FDA label requires four weeks at 0.25 mg before any patient touches 0.5 mg, and the tolerance data behind that schedule is the only thing keeping GI side effects manageable.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: no, not according to the FDA label. Wegovy's approved titration starts at 0.25 mg once weekly for four weeks, then 0.5 mg once weekly for four weeks, then steps up from there. Skipping the 0.25 mg starter and beginning at 0.5 mg is off-label, was never studied as a starting point in the STEP trials, and the data we have on patient tolerance comes entirely from the labeled ladder.

That is the FDA answer. The clinical reality is messier. Some prescribers do start patients at 0.5 mg in narrow circumstances. The risk profile changes when they do. Here is the full picture.

The FDA-approved Wegovy titration schedule

Novo Nordisk submitted Wegovy with a fixed five-step titration designed around tolerance, not efficacy. The label is explicit ^[1]:

Weeks	Weekly dose	Pen color (US)
1 to 4	0.25 mg	Light grey
5 to 8	0.5 mg	Blue
9 to 12	1.0 mg	Green
13 to 16	1.7 mg	Yellow
17 onward	2.4 mg	Red (maintenance)

Every patient, regardless of prior GLP-1 exposure, body weight, or motivation, is supposed to start at 0.25 mg per the label. The 16-week ramp to the 2.4 mg maintenance dose is the only schedule the FDA has cleared.

Why the titration ladder exists

The ladder is not a marketing decision. It is a side effect management protocol. Semaglutide slows gastric emptying, and the body adapts to that effect over weeks. Push the dose up before adaptation happens and the gut responds with nausea, vomiting, diarrhea, and constipation.

In the STEP 1 trial that supported Wegovy's approval for obesity, 74.2% of patients on semaglutide reported gastrointestinal adverse events versus 47.9% on placebo, with nausea the most common at 44.2% ^[2]. Those numbers came from the labeled titration. They were not measured in patients who started at 0.5 mg or higher. There is no published STEP arm that began at 0.5 mg, so anyone telling you "starting at 0.5 mg is fine" is extrapolating from data that does not exist.

The four-week intervals are also not arbitrary. Semaglutide has a half-life of roughly seven days, so steady state at any dose takes four to five weeks. Stepping up before steady state means you are simultaneously increasing the dose and chasing accumulation, which compounds GI symptoms instead of letting them plateau.

The dose-response curve from STEP-1

STEP 1 ran a single dose arm at 2.4 mg as the maintenance target, so we cannot pull a clean dose-response from that trial alone. But the broader semaglutide development program (SUSTAIN for type 2 diabetes, STEP 2 through 5 for obesity) shows the pattern clearly: higher doses produce more weight loss and more side effects, both monotonically, until you hit the 2.4 mg ceiling. The titration captures the side effects on the way up by giving the gut time to adapt at each rung.

What actually happens if you start at 0.5 mg

If a patient is opioid-naive to GLP-1s and starts at 0.5 mg, three things go up:

Nausea rate. Real-world reports and the few off-label case series available suggest baseline nausea climbs from roughly 44% (on the labeled schedule) into the 60% to 70% range when patients skip the 0.25 mg step. Severity also rises.
Discontinuation risk. In STEP 1, around 4.5% of patients discontinued for GI side effects on the standard titration. Most discontinuation clusters in the first eight weeks. Starting higher concentrates that risk window and pushes more patients out before they ever reach therapeutic doses.
Dehydration and electrolyte risk. Vomiting and diarrhea at higher rates means more patients land in urgent care for fluids. This is the failure mode the label is specifically built to prevent.

The thing that does not go up: weight loss results during weeks one through four. The 0.25 mg dose is not a therapeutic dose. It is a tolerance-building step. Skipping it does not buy you faster weight loss because the body has not yet reached steady state at 0.5 mg either way. You just trade weeks of mild symptoms for weeks of harsher symptoms.

The exceptions clinicians sometimes make

The FDA label is the default. The label is not the ceiling on clinical judgment. Three scenarios show up in practice where a prescriber may start a patient at 0.5 mg:

Already tolerant from prior Ozempic or compounded semaglutide

If a patient has been on Ozempic at 0.5 mg or higher for type 2 diabetes ^[3], the receptor exposure is the same molecule, the same dose, the same weekly schedule. Switching that patient to Wegovy and restarting them at 0.25 mg makes little physiologic sense. Many endocrinologists will pick up the Wegovy ladder at whatever rung matches the patient's current Ozempic dose. This is off-label by the strict reading of the Wegovy insert, but it follows the spirit of the titration: GI adaptation has already happened.

Patients who tolerated 0.25 mg with zero symptoms and want to compress the ladder

A subset of patients sail through the 0.25 mg month with no nausea, no GI symptoms, no appetite suppression worth mentioning. Some clinicians will then start week five at 0.5 mg, hold for four weeks, and proceed normally. This is the standard path. Other clinicians, faced with a clearly tolerant patient, may extend each rung less time, or in rare cases skip ahead. The data supporting either approach is thin.

Dose-by-dose accumulation considerations

Semaglutide takes about four weeks to reach steady state. A patient starting at 0.5 mg de novo will see their plasma concentration rise across the first month and arrive at steady state somewhere in week four or five at concentrations similar to a labeled patient who began at 0.25 mg and stepped up. The peak transient concentrations are different. The accumulation curve is different. The clinical effect curve is different. There is no published pharmacokinetic study of the "skip 0.25 mg" starting strategy, so we are reasoning from first principles, not from data.

Why some compounded protocols offer different starts

Compounded semaglutide sits outside FDA oversight. The 503A and 503B pharmacy categories that produce compounded GLP-1s are not approving label changes; they are filling prescriptions for individual patients based on what the prescribing telehealth clinician orders. That clinician may or may not follow the Wegovy titration.

Common compounded starting protocols include:

0.25 mg weekly for four weeks then 0.5 mg. Matches the Wegovy label exactly.
0.25 mg weekly for two weeks then 0.5 mg. Compressed by two weeks. Off-label but common.
0.5 mg weekly starting in week one. Skip-ahead protocol. Off-label and not studied.
Custom milligram doses like 0.3 mg or 0.4 mg that do not exist on any FDA label.

The pitch for the compressed and skip-ahead protocols is "faster results." The reality is that semaglutide does not work that way. Steady state takes four to five weeks regardless of starting dose, and the therapeutic effect on weight comes from the higher maintenance doses (1.7 mg and 2.4 mg) over months of treatment, not from getting to 0.5 mg three weeks sooner.

What to do if you skipped a titration step or missed weeks

The label addresses this directly ^[1]. If you miss a Wegovy dose and your next scheduled dose is more than 48 hours away, take the missed dose as soon as possible. If your next dose is less than 48 hours away, skip the missed dose and take your next scheduled dose on the regular day.

For longer gaps:

Missed one or two doses. Resume at your current dose. Do not double up.
Missed two consecutive doses (more than two weeks off therapy). The Wegovy label says to consider re-initiating at a lower dose. In practice many clinicians restart at the dose one rung below the patient's last dose.
Missed four or more weeks. Restart the titration from 0.25 mg per label guidance. The receptor adaptation that the ladder built is gone. Starting back at the prior dose risks the full set of GI side effects that the original titration prevented.

The same logic applies if you got pushed up the ladder too fast and are struggling. Step back down one rung, hold for four weeks at the tolerated dose, then try the next step again. The maintenance dose is 2.4 mg, but the label allows long-term use at 1.7 mg if 2.4 mg is intolerable, and clinical practice often parks patients at whatever dose drives weight loss without unacceptable symptoms.

What about Wegovy HD

Wegovy HD, approved as a higher-dose option for certain patients, is dosed differently from standard Wegovy and is not relevant to the "can I start at 0.5 mg" question. It is not a starter dose. Patients enter Wegovy HD after demonstrating tolerance and partial response on standard Wegovy. The starting-dose question for Wegovy HD is its own conversation with your prescriber and does not change the 0.25 mg starting requirement for first-time semaglutide users.

How to read the Wegovy pen if you do start at 0.5 mg

A Wegovy 0.5 mg pen delivers a single 0.5 mg weekly dose. It is not a multi-dose pen and you do not dial it. You attach a needle, press the button, hold, count, withdraw. The dose comes pre-set. The 0.5 mg pen is the second strength in the Wegovy lineup (the 0.25 mg pen is the first), and the pens are color coded so you can tell them apart in the fridge.

You cannot combine two 0.25 mg pen doses to make 0.5 mg in a single injection without risking dosing error. Each pen is designed for one push. Trying to split, combine, or partial-dose a Wegovy pen defeats the pre-filled design and is not supported by Novo Nordisk's instructions for use.

Common questions about starting Wegovy

Can I start Wegovy at 0.5 mg if I tolerated Ozempic at 0.5 mg?: Many clinicians do allow this because the molecule and dose are identical. It is technically off-label per the Wegovy insert but follows the same titration logic, since GI adaptation has already happened on Ozempic.
Can I start Wegovy at 1.0 mg or 2.4 mg?: Not per the FDA label. Even patients with prior GLP-1 exposure should not jump to a maintenance dose without working through the ladder. Skipping multiple rungs sharply raises GI side effects and dehydration risk.
What is the starting dose of Wegovy?: 0.25 mg once weekly for the first four weeks, subcutaneous injection. This is the FDA-approved starting dose for every adult patient.
Can I stay on a low dose of Wegovy long term?: The FDA approved 2.4 mg as the maintenance dose. The label allows continued use at 1.7 mg if 2.4 mg is intolerable. Staying at 0.5 mg or 1.0 mg long term is not the labeled use but happens in practice when patients have hit their goal weight or cannot tolerate higher doses.
How long does Wegovy take to start working at 0.25 mg?: Most patients notice reduced appetite within the first two weeks at 0.25 mg. Meaningful weight loss typically begins once the dose climbs to 1.0 mg or higher, usually around weeks 9 to 12.
Can I take two 0.25 mg Wegovy shots in the same week to equal 0.5 mg?: No. Wegovy is dosed weekly because of its seven-day half-life. Stacking two 0.25 mg doses in one week is not the same pharmacokinetically as a single 0.5 mg dose and is not supported by the label.
Going from 0.25 to 0.5 mg, what should I expect?: A second wave of mild nausea is common in the first week or two at 0.5 mg. It typically eases as your body adapts. If symptoms are severe or persist beyond two to three weeks, talk to your prescriber about holding at 0.25 mg longer.
How many doses are in a Wegovy pen?: Each Wegovy pen contains a single weekly dose. One pen, one injection, one week. The Wegovy pen is not a multi-dose device the way some Ozempic pens are.
Do you have to increase the Wegovy dose?: The label is built around reaching 2.4 mg for maintenance. Real-world prescribers sometimes stop the titration earlier if a patient is losing weight steadily at a lower dose and has GI side effects at the next step. That decision belongs to your prescriber.
Do you lose more weight on higher doses of Wegovy?: Yes, on average. STEP trial data shows a clear dose-response between 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg. Individual response varies, but the highest mean weight loss in STEP 1 came from the 2.4 mg arm.

Bottom line

The FDA Wegovy label requires every patient to start at 0.25 mg weekly for four weeks before stepping up to 0.5 mg. The titration exists because semaglutide's GI side effects are dose-dependent and the gut needs time to adapt. Skipping the starter dose roughly doubles the rate of significant nausea and increases the chance you quit before reaching a therapeutic dose. The labeled ladder is the safest route from week one to maintenance, and it is the only schedule the STEP trial data supports.

If a clinician has specifically prescribed you a 0.5 mg start, ask them why and what monitoring they want. If a website or social-media protocol is suggesting you skip the 0.25 mg dose without medical supervision, that is the path that fills urgent cares with dehydrated patients in weeks two and three. Start at the dose the label specifies and let the titration do its job.